Drugs / FPI-1434
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03746431 | Jan 2019 → Dec 2025 | adrenal cortex carcinoma, cervical cancer, endometrial cancer, head and neck squamous cell carcinoma +3 | Fusion Pharmaceuticals Inc. | Terminated | Met primary Stop: Business |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-06-27 | Fusion Pharmaceuticals Inc. | Results Dose-Escalation Study of [225Ac]-FPI-1434 in Patients With IGF-1R-Expressing Advanced Solid Tumors: Preliminary Pharmacology and Dosimetry Results fusionpharma.com ↗
Dose-Escalation Study of [225Ac]-FPI-1434 (FPI-1434) in Patients With IGF-1R-Expressing Advanced Solid Tumors: Preliminary Pharmacology and Dosimetry Results (NCT03746431) |
| 2021-06-14 | Fusion Pharmaceuticals Inc. | Results Preliminary Dosimetry Results from a First-in-Human Phase 1 Study Evaluating the Efficacy and Safety of [225Ac]-FPI-1434 in Patients with IGF-1R Expressing Solid Tumors fusionpharma.com ↗
Preliminary Dosimetry Results from a First-in-Human Phase 1 Study Evaluating the Efficacy and Safety of [225Ac]-FPI-1434 in Patients with IGF-1R Expressing Solid Tumors |
| 2021-06-14 | Fusion Pharmaceuticals Inc. | Results Preliminary Dosimetry Results from a First-in-Human Phase 1 Study Evaluating the Efficacy and Safety of [225Ac]-FPI-1434 in Patients with IGF-1R Expressing Solid Tumors (Poster) fusionpharma.com ↗ |
| 2021-06-14 | Fusion Pharmaceuticals Inc. | Results Combination of IGF-1R Targeted Alpha Therapy with Olaparib Results in Synergistic Efficacy Against Colorectal and Lung Cancer Xenografts fusionpharma.com ↗
Combination of IGF-1R targeted alpha therapy with olaparib results in synergistic efficacy against colorectal and lung cancer xenografts. |
| 2021-05-05 | Fusion Pharmaceuticals Inc. | Results Combination of IGF-1R Targeted Alpha Therapy with Olaparib Results in Synergistic Efficacy Against Colorectal and Lung Cancer Xenografts fusionpharma.com ↗
Combination of IGF-1R Targeted Alpha Therapy with Olaparib Results in Synergistic Efficacy Against Colorectal and Lung Cancer Xenografts |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FPI-1434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03746431 ↗ |
| Known as | [225Ac]-FPI-1434 | “[225Ac]-FPI-1434 Injection multi-dose” NCT03746431 ↗ |